|Application ||WB, IHC-P, E|
|Calculated MW||99421 Da|
|Antigen Region||463-492 aa|
|Other Names||Serine/threonine-protein kinase N3, Protein kinase PKN-beta, Protein-kinase C-related kinase 3, PKN3, PKNBETA|
|Target/Specificity||This PKN beta antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 463-492 amino acids from the C-terminal region of human PKN beta.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PKN beta Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Contributes to invasiveness in malignant prostate cancer.|
|Cellular Location||Nucleus. Cytoplasm, perinuclear region Note=Nuclear and perinuclear Golgi region|
|Tissue Location||Expressed in prostate tumors and various cancer cell lines. Not expressed in adult tissues|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PKN3, a protein kinase C-related molecule, mediates malignant cell growth downstream of activated PI3K. PKN3 is required for invasive prostate cell growth as assessed by 3D cell culture assays and in an orthotopic mouse tumor model by inducible expression of short hairpin RNA (shRNA). PKN3 is regulated by PI3K at both the expression level and the catalytic activity level. Therefore, PKN3 might represent a preferred target for therapeutic intervention in cancers that lack tumor suppressor PTEN function or depend on chronic activation of PI3K.
Oishi, K., et al., Biochem. Biophys. Res. Commun. 261(3):808-814 (1999).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.